(Total Views: 555)
Posted On: 03/13/2025 10:08:08 AM
Post# of 154873
The hidden scars of ulcerative colitis: A Q&A with Amy Lightner
"In UC, however, this rigidity appeared to come from scarring of the submucosal layer, suggesting there may be a role for antifibrotics in chronic UC. The main issue is that submucosal fibrosis in UC may contribute to persistent symptoms and unresponsiveness to standard anti-inflammatory treatment."
"The efficacy of FDA-approved advanced therapies remains limited. Despite the increased number of available treatments targeting different inflammatory pathways, we have yet to find a therapy that works for more than half of patients."
Wonder if Dr. Lightner would be interested in trialing leronlimab.
https://magazine.scripps.edu/profiles/2025/on...-lightner/
"In UC, however, this rigidity appeared to come from scarring of the submucosal layer, suggesting there may be a role for antifibrotics in chronic UC. The main issue is that submucosal fibrosis in UC may contribute to persistent symptoms and unresponsiveness to standard anti-inflammatory treatment."
"The efficacy of FDA-approved advanced therapies remains limited. Despite the increased number of available treatments targeting different inflammatory pathways, we have yet to find a therapy that works for more than half of patients."
Wonder if Dr. Lightner would be interested in trialing leronlimab.
https://magazine.scripps.edu/profiles/2025/on...-lightner/
(9)
(0)
